A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

August 5, 2024

Study Completion Date

August 5, 2024

Conditions
Gaucher Disease
Interventions
DRUG

Velaglucerase Alfa

VPRIV intravenous infusion every other week for 60 minutes.

Trial Locations (10)

100039

Chinese PLA General Hospital, Beijing

100045

Beijing Children's Hospital, Capital Medical University, Beijing

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

210008

Nanjing Children's Hospital, Nanjing

300020

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

430030

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan

510080

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

510623

Guangzhou Women and Children's Medical Center, Guangzhou

730030

Lanzhou University Second Hospital, Lanzhou

050000

The Second Hospital of Hebei Medical University, Shijiazhuang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05529992 - A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease | Biotech Hunter | Biotech Hunter